ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2130

Primary Prevention of Myocardial Infarction in Rheumatoid Arthritis Using Low-Dose Aspirin: A Case-Crossover Study

Josefina Durán Santa Cruz1, Yuqing Zhang2 and David T. Felson3, 1Department of Rheumatology, Pontificia Universidad Católica de Chile School of Medicine, Santiago, Chile, 2Clinical Epidemilogy and Training Unit, Boston University School of Medicine, Boston, MA, 3Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: aspirin, Cardiovascular disease and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Rheumatoid Arthritis - Clinical Aspects III - Cardiovascular Disease and RA

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose:

Subjects with rheumatoid arthritis (RA) are at a higher risk of developing cardiovascular (CV) disease which is the leading cause of death in subjects with RA. In the general population, there is unequivocal evidence supporting ASA as secondary prophylaxis for CV events, but its efficacy as primary prevention has been questioned. There is currently no consensus regarding use of ASA as primary prophylaxis and it is necessary to identify if its use is justified in particular risk profile groups. We performed a case-crossover study in RA subjects, to evaluate if a protective association exists between ASA use and myocardial infarction (MI).

Methods:

THIN, a population-based UK database, containing data provided from general practitioners was used. We included records between 1/1/1995 and 9/30/2013. In the UK persons over age 60 get free ASA by prescription and 75% of use is by prescription. Subjects >60 years with RA, defined as one RA read code and one DMARD code within a year, constituted our study population. We excluded all subjects with history of MI, angina prior to study initiation or a coronary artery procedure (stent/coronary artery bypass graft) prior to the index date. To be included subjects had to have an incident MI/angina or a fatal MI. Each subject contributed two observations: a “case observation” and a “control observation”. For “case observations”, the index date was the MI/angina date. For “control observations”, the control date was 90 days prior to the index date. An individual was considered exposed if he/she used ASA within 7 days prior to the index date/control date. In addition, we examined effect of ASA use within 15 and zero days prior to the event. A conditional logistic regression was performed adjusting for drugs that are potential confounders (antiaggregants-anticoagulants, antihypertensives, NSAIDS, lipid-lowering drugs, glucocorticoids, nitrates). A sensitivity analysis was performed looking at males. As a secondary outcome we looked at MI and fatal MI.

Results:

We identified 705 RA patients who experienced incident MI/angina during the study period. The characteristics of the study subjects are described in Table 1. During the case period 192 subjects were exposed to ASA and during the control period 156 subjects were exposed, with 96 discordant exposure statuses within a subject in the two observation periods. There was no significant association between ASA use and CV events after adjusting for potential confounders (1.20 (0.73, 1.96)). When analysis was restricted to men, we again found no association was present (adjusted OR 1.12 (0.49, 2.52)). Findings were similar when considering MI as our outcome and when restricting exposure to 15 and zero days prior to the index date.

Conclusion:

This study suggests ASA is not effective in RA as primary prophylaxis.

Table 1. Study population characteristics.

 

Subjects (n)

705

Age (years, SD)

72.6 +- 7.2

Female

 

400 (56.7%)

Atrial Fibrillation

71 (10.1%)

Chronic Kidney Disease

103 (14.6%)

COPD

80 (11.3%)

Diabetes

114 (16.2%)

Dyslipidemia

79 (11.2%)

Hypertension

355 (50.4%)

Peripheral Vascular Disease

41 (5.8%)

Stroke

65 (9.2%)

AntiHypertensives

487 (69.1%)

Antiagregants/Anticoagulants

90 (12.8%)

Glucocorticoids

314 (44.5%)

Lipid-Lowering Drugs

215 (30.5%)

Nitrates

150 (21.3%)

NSAIDS

393 (55.7%)

Alcohol

non-drinker

168 (23.8%)

ex-drinker

22 (3.1%)

current drinker

438 (62.1%)

missing

77 (10.9%)

BMI (continuous, kg/m2)

27.0 +- 4.8

BMI (categorical)

underweight

27 (3.8%)

normal

155 (22.0%)

overweight

219 (31.1%)

obese

125 (17.7%)

missing

179 (25.4%)

 

 

 

GP visits

10 +- 13

Hospital visits

1 +- 1

RA Duration (years, SD)

6.4 +- 4.6

Smoking

non-smoker

284 (40.3%)

ex-smoker

253 (35.9%)

current smoker

138 (19.6%)

missing

30 (4.3%)

                                                                                           


Disclosure: J. Durán Santa Cruz, None; Y. Zhang, None; D. T. Felson, None.

To cite this abstract in AMA style:

Durán Santa Cruz J, Zhang Y, Felson DT. Primary Prevention of Myocardial Infarction in Rheumatoid Arthritis Using Low-Dose Aspirin: A Case-Crossover Study [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/primary-prevention-of-myocardial-infarction-in-rheumatoid-arthritis-using-low-dose-aspirin-a-case-crossover-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/primary-prevention-of-myocardial-infarction-in-rheumatoid-arthritis-using-low-dose-aspirin-a-case-crossover-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology